133 related articles for article (PubMed ID: 23113686)
1. Treatment of invasive candidiasis in neutropenic patients: systematic review of randomized controlled treatment trials.
Kanji JN; Laverdière M; Rotstein C; Walsh TJ; Shah PS; Haider S
Leuk Lymphoma; 2013 Jul; 54(7):1479-87. PubMed ID: 23113686
[TBL] [Abstract][Full Text] [Related]
2. Echinocandins vs. amphotericin B against invasive candidiasis in children and neonates: A meta-analysis of randomized controlled trials.
Chen YH; Cheng IL; Lai CC; Tang HJ
Int J Antimicrob Agents; 2019 Jun; 53(6):789-794. PubMed ID: 30831231
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Echinocandins for the Treatment of Invasive Candidiasis in Children: A Meta-analysis.
Tsekoura M; Ioannidou M; Pana ZD; Haidich AB; Antachopoulos C; Iosifidis E; Kolios G; Roilides E
Pediatr Infect Dis J; 2019 Jan; 38(1):42-49. PubMed ID: 29596219
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of amphotericin B, azoles and echinocandins in the treatment of candidemia and invasive candidiasis: A systematic review and network meta-analysis.
Demir KK; Butler-Laporte G; Del Corpo O; Ekmekjian T; Sheppard DC; Lee TC; Cheng MP
Mycoses; 2021 Sep; 64(9):1098-1110. PubMed ID: 33894072
[TBL] [Abstract][Full Text] [Related]
5. Systematic review on the first line treatment of amphotericin B in critically ill adults with candidemia or invasive candidiasis.
Keane S; Geoghegan P; Povoa P; Nseir S; Rodriguez A; Martin-Loeches I
Expert Rev Anti Infect Ther; 2018 Nov; 16(11):839-847. PubMed ID: 30257597
[TBL] [Abstract][Full Text] [Related]
6. [Management of invasive candidiasis in non-neutropenic patient].
Cardozo C; Mensa J
Rev Esp Quimioter; 2015 Sep; 28 Suppl 1():34-7. PubMed ID: 26365732
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy of echinocandins and nonechinocandins for the treatment of Candida parapsilosis Infections: a meta-analysis.
Kale-Pradhan PB; Morgan G; Wilhelm SM; Johnson LB
Pharmacotherapy; 2010 Dec; 30(12):1207-13. PubMed ID: 21114387
[TBL] [Abstract][Full Text] [Related]
8. Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients.
Johansen HK; Gotzsche PC
Cochrane Database Syst Rev; 2000; (3):CD000239. PubMed ID: 10908468
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of micafungin for invasive candida infections: a meta-analysis of randomized controlled trials.
Chen Q; Lin MH; Chen ML; Liu ZY; Chai D; Wang R
Chin Med J (Engl); 2012 Jan; 125(2):345-51. PubMed ID: 22340571
[TBL] [Abstract][Full Text] [Related]
10. Candidemia and invasive candidiasis in adults: A narrative review.
Antinori S; Milazzo L; Sollima S; Galli M; Corbellino M
Eur J Intern Med; 2016 Oct; 34():21-28. PubMed ID: 27394927
[TBL] [Abstract][Full Text] [Related]
11. Invasive candidiasis in the neutropenic patient.
Fortún J; Gioia F
Rev Esp Quimioter; 2017 Sep; 30 Suppl 1():22-25. PubMed ID: 28882010
[TBL] [Abstract][Full Text] [Related]
12. Treatment of invasive candidal infections: systematic review and meta-analysis.
Gafter-Gvili A; Vidal L; Goldberg E; Leibovici L; Paul M
Mayo Clin Proc; 2008 Sep; 83(9):1011-21. PubMed ID: 18775201
[TBL] [Abstract][Full Text] [Related]
13. Comparison of caspofungin and amphotericin B for invasive candidiasis.
Mora-Duarte J; Betts R; Rotstein C; Colombo AL; Thompson-Moya L; Smietana J; Lupinacci R; Sable C; Kartsonis N; Perfect J;
N Engl J Med; 2002 Dec; 347(25):2020-9. PubMed ID: 12490683
[TBL] [Abstract][Full Text] [Related]
14. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
Ou HT; Lee TY; Chen YC; Charbonneau C
BMC Infect Dis; 2017 Jul; 17(1):481. PubMed ID: 28693479
[TBL] [Abstract][Full Text] [Related]
15. Invasive candidiasis in cancer patients: observations from a randomized clinical trial.
DiNubile MJ; Hille D; Sable CA; Kartsonis NA
J Infect; 2005 Jun; 50(5):443-9. PubMed ID: 15907554
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.
Chandrasekar P; Sirohi B; Seibel NL; Hsu JW; Azie N; Wu C; Ruhnke M
Mycoses; 2018 May; 61(5):331-336. PubMed ID: 29364548
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
[TBL] [Abstract][Full Text] [Related]
18. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials.
Bow EJ; Laverdière M; Lussier N; Rotstein C; Cheang MS; Ioannou S
Cancer; 2002 Jun; 94(12):3230-46. PubMed ID: 12115356
[TBL] [Abstract][Full Text] [Related]
19. Antifungal agents for invasive candidiasis in non-neutropenic critically ill adults: What do the guidelines recommend?
Wang Y; McGuire TM; Hollingworth SA; Dong Y; Van Driel ML
Int J Infect Dis; 2019 Dec; 89():137-145. PubMed ID: 31639522
[TBL] [Abstract][Full Text] [Related]
20. EPICO 2.0 project. Development of educational therapeutic recommendations using the DELPHI technique on invasive candidiasis in critically ill adult patients in special situations.
Zaragoza R; Ferrer R; Maseda E; Llinares P; Rodriguez A;
Rev Iberoam Micol; 2014; 31(3):157-75. PubMed ID: 25113990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
